{"id":"W2042060010","doi":"10.1089/apc.2012.0135","title":"A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy","year":2012,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; National Institute of Mental Health; EMD Serono; National Institutes of Health; International AIDS Society; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Ontario HIV Treatment Network; National Institute on Aging; Bristol-Myers Squibb","keywords":"Raltegravir; Medicine; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Virology; Integrase inhibitor; Reverse transcriptase; Human immunodeficiency virus (HIV); Randomized controlled trial; Pharmacology; Internal medicine; Antiretroviral therapy; Viral load; Polymerase chain reaction; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003912879,0.0003276555,0.001029384,0.0003422636,0.00007167267,0.00001345309,0.00003936283,0.0001094686,0.00005295278],"category_scores_gemma":[0.0001626876,0.0001988369,0.000153876,0.0003421095,0.0001029433,0.0001521304,0.00002421534,0.000128578,0.000003642844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002203882,"about_ca_system_score_gemma":0.0002658641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005023928,"about_ca_topic_score_gemma":0.00001145417,"domain_scores_codex":[0.9980114,0.0001363887,0.0006836585,0.0003350759,0.0003645751,0.0004689119],"domain_scores_gemma":[0.9989291,0.0001550243,0.0001866198,0.0002627683,0.0001664936,0.00029997],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9379207,0.00136522,0.005941737,0.0004532748,0.000310498,0.00002919276,0.02111481,6.133438e-7,0.0009079455,0.00002460103,0.0006986033,0.03123276],"study_design_scores_gemma":[0.907651,0.072258,0.00006827969,0.0005673168,0.0004808912,0.000009700156,0.004361702,0.00001741782,0.01045687,0.000007131252,0.003814784,0.0003068785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908016,0.0002640802,0.00008127296,0.00005624073,0.0002168522,0.008247762,0.00008765355,0.00003031902,0.0002142272],"genre_scores_gemma":[0.990508,0.00005929188,0.004939923,0.0001046662,0.0001525889,0.003095554,0.0001829729,0.00003855089,0.0009184917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07089277,"threshold_uncertainty_score":0.8108333,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01113792086951531,"score_gpt":0.2463106696918898,"score_spread":0.2351727488223745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}